BrainStorm Cell Therapeutics Company Profile (NASDAQ:BCLI)

About BrainStorm Cell Therapeutics

BrainStorm Cell Therapeutics logoBrainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson's disease (PD), among others. Its subsidiary, Brainstorm Cell Therapeutics Ltd. (the Israeli Subsidiary), holds rights to commercialize the technology, NurOwn. NurOwn is in clinical development for the treatment of ALS. The Company has completed over two clinical trials of NurOwn in patients with ALS at Hadassah Medical Center (Hadassah). The first study, a Phase I/II safety and efficacy study of NurOwn in ALS patients administered either intramuscularly or intrathecally. The Company conducted Phase IIa combined (intramuscular and intrathecal) treatment, dose-escalating trial. It had completed treatment of over 10 patients in its ALS Phase IIa NurOwn dose-escalating clinical trial.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: BCLI
  • CUSIP:
Key Metrics:
  • Previous Close: $2.43
  • 50 Day Moving Average: $2.44
  • 200 Day Moving Average: $2.45
  • 52-Week Range: $18,654,000.00 - $1.90
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.00
  • P/E Growth: 0.00
  • Market Cap: $45.52M
  • Outstanding Shares: 18,654,000
  • Beta: 1.84
Profitability:
  • Return on Equity: -49.85%
  • Return on Assets: -43.21%
Debt:
  • Current Ratio: 10.01%
  • Quick Ratio: 10.01%
Additional Links:
Companies Related to BrainStorm Cell Therapeutics:

Analyst Ratings

Consensus Ratings for BrainStorm Cell Therapeutics (NASDAQ:BCLI) (?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $5.00 (104.92% upside)

Analysts' Ratings History for BrainStorm Cell Therapeutics (NASDAQ:BCLI)
Show:
DateFirmActionRatingPrice TargetDetails
8/11/2016Maxim GroupSet Price TargetBuy$5.00View Rating Details
(Data available from 9/26/2014 forward)

Earnings

Earnings History for BrainStorm Cell Therapeutics (NASDAQ:BCLI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/15/2016        
8/11/2016Q2($0.18)($0.05)ViewN/AView Earnings Details
5/10/2016Q116($0.25)($0.10)ViewN/AView Earnings Details
11/17/2015Q3($0.14)($0.14)ViewN/AView Earnings Details
8/13/2015Q215($0.13)($0.12)ViewListenView Earnings Details
5/14/2015Q115($0.14)($0.12)ViewListenView Earnings Details
3/26/2015Q414($0.18)($0.18)ViewN/AView Earnings Details
11/13/2014($0.12)($0.16)ViewN/AView Earnings Details
11/13/2014Q3 14($0.16)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for BrainStorm Cell Therapeutics (NASDAQ:BCLI)
Current Year EPS Consensus Estimate: $-0.34 EPS
Next Year EPS Consensus Estimate: $-0.61 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.08)($0.08)($0.08)
Q2 20161($0.10)($0.10)($0.10)
Q3 20161($0.10)($0.10)($0.10)
Q4 20161($0.09)($0.09)($0.09)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for BrainStorm Cell Therapeutics (NASDAQ:BCLI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for BrainStorm Cell Therapeutics (NASDAQ:BCLI)
Insider Ownership Percentage: 23.70%
Institutional Ownership Percentage: 8.74%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/16/2015Robert G L ShorrDirectorSell10,800$2.71$29,268.00View SEC Filing  
12/15/2015Malcolm S. TaubDirectorSell41,742$2.60$108,529.20View SEC Filing  
12/11/2015Malcolm S. TaubDirectorSell13,480$2.73$36,800.40View SEC Filing  
10/1/2015International Holdings Ltd AccMajor ShareholderBuy2,000$2.58$5,160.00View SEC Filing  
9/30/2015International Holdings Ltd AccMajor ShareholderBuy9,200$2.34$21,528.00View SEC Filing  
8/20/2015Yoram BibringCFOBuy8,500$3.04$25,840.00View SEC Filing  
8/17/2015Yoram BibringCFOBuy41,500$2.92$121,180.00View SEC Filing  
10/10/2014International Holdings Ltd AccMajor ShareholderBuy8,600$4.06$34,916.00View SEC Filing  
10/1/2014International Holdings Ltd AccMajor ShareholderBuy6,700$4.14$27,738.00View SEC Filing  
9/22/2014International Holdings Ltd AccMajor ShareholderBuy11,000$4.17$45,870.00View SEC Filing  
9/15/2014Anthony S FiorinoCEOBuy18,000$0.28$5,040.00View SEC Filing  
6/16/2014International Holdings Ltd AccMajor ShareholderBuy130,000$0.29$37,700.00View SEC Filing  
6/13/2014International Holdings Ltd AccMajor ShareholderBuy150,000$0.35$52,500.00View SEC Filing  
4/28/2014International Holdings Ltd AccMajor ShareholderBuy939,600$0.30$281,880.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for BrainStorm Cell Therapeutics (NASDAQ:BCLI)
DateHeadline
News IconKeen Investors Find News on Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - Duncan Research (NASDAQ:BCLI)
www.duncanindependent.com - September 24 at 3:40 PM
News IconPenny Stock Investors Keen on Shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - Duncan Research (NASDAQ:BCLI)
www.duncanindependent.com - September 22 at 9:39 AM
News IconUnder the Microscope: Getting a Closer Look at Shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - Duncan Research (NASDAQ:BCLI)
www.duncanindependent.com - September 20 at 3:43 PM
News IconPenny Stock Investors Take an Interest in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - Duncan Research (NASDAQ:BCLI)
www.duncanindependent.com - September 20 at 3:43 PM
News IconBrainstorm Cell Therapeutics Inc (BCLI) Stock Rating Reaffirmed by Maxim Group - DailyQuint (NASDAQ:BCLI)
dailyquint.com - September 20 at 3:43 PM
News IconKeen Investors Seek Information on Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - Duncan Research (NASDAQ:BCLI)
www.duncanindependent.com - September 16 at 3:45 PM
News IconKeen Investors Narrowing Their Focus on Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - Duncan Research (NASDAQ:BCLI)
www.duncanindependent.com - September 15 at 9:27 PM
News IconStock Update, a Closer Look at Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - Duncan Research (NASDAQ:BCLI)
www.duncanindependent.com - September 15 at 4:19 PM
News IconPenny Stock Investors Highly Curious in Shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - Duncan Research (NASDAQ:BCLI)
www.duncanindependent.com - September 13 at 4:47 PM
finance.yahoo.com logoBrainStorm CEO to Present at Two Investor Conferences in September (NASDAQ:BCLI)
finance.yahoo.com - September 6 at 8:37 AM
finance.yahoo.com logoBCLI: Planning for Phase 3 Study of NurOwn™ in ALS Following Successful Phase 2 Results (NASDAQ:BCLI)
finance.yahoo.com - August 25 at 3:49 PM
finance.yahoo.com logoBrainStorm's Valuation Doesn't Reflect Potential Value of NurOwn(R) Therapy (NASDAQ:BCLI)
finance.yahoo.com - August 16 at 12:29 PM
streetinsider.com logoBrainstorm Cell Therapeutics (BCLI) Tops Q2 EPS by 13c - StreetInsider.com (NASDAQ:BCLI)
www.streetinsider.com - August 12 at 3:59 PM
streetinsider.com logoForm 10-Q BRAINSTORM CELL THERAPEU For: Jun 30 (NASDAQ:BCLI)
www.streetinsider.com - August 11 at 12:51 PM
News IconIncreased Stock Volatility Watch: Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - Engelwood Daily (NASDAQ:BCLI)
www.engelwooddaily.com - July 21 at 3:46 PM
News IconShares Losing Ground in Trade: Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - TGP (NASDAQ:BCLI)
telanaganapress.com - July 21 at 3:46 PM
news.cmlviz.com logoBrainstorm Cell Therapeutics Inc (NASDAQ:BCLI) Price Volatility Hits An Extreme High - CML News (NASDAQ:BCLI)
news.cmlviz.com - July 21 at 3:46 PM
live-pr.com logoNew Market Research Report: BrainStorm Cell Therapeutics Inc. (BCLI) - Financial and Strategic SWOT Analysis Review (NASDAQ:BCLI)
www.live-pr.com - July 20 at 11:50 AM
kcregister.com logoBrainstorm Cell Therapeutics (NASDAQ:BCLI) Announces NurOwn Phase 2 Met Primary Endpoint: Progenics ... - KC Register (NASDAQ:BCLI)
www.kcregister.com - July 19 at 3:47 PM
News IconShares Losing Ground in Session: Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - TGP (NASDAQ:BCLI)
telanaganapress.com - July 19 at 3:47 PM
seekingalpha.com logoBrainstorm's NurOwn cells better than placebo in ALS patients, but more complete data needed; shares up 5% premarket (NASDAQ:BCLI)
seekingalpha.com - July 19 at 9:57 AM
nasdaq.com logoWhat''s In Store For BCLI: A Smooth Sailing Or Perfect Storm? (NASDAQ:BCLI)
www.nasdaq.com - July 19 at 9:57 AM
News IconInvestor Watch: Volatility Recap on Shares of: Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - Engelwood Daily (NASDAQ:BCLI)
www.engelwooddaily.com - July 18 at 3:50 PM
News IconMost Volatile Healthcare Stocks- Synergy Pharmaceuticals (NASDAQ:SGYP), Brainstorm Cell Therapeutics (NASDAQ ... - Seneca Globe (NASDAQ:BCLI)
www.senecaglobe.com - July 18 at 3:50 PM
News IconStock Declining in Trading Session: Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - TGP (NASDAQ:BCLI)
telanaganapress.com - July 18 at 3:50 PM
News IconBrainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) Is About To Release Clinical Study Results - Scibility Media (NASDAQ:BCLI)
scibilitymedia.com - July 18 at 3:50 PM
finance.yahoo.com logoBCLI: Phase 2 ALS Trial Shows Clinical Benefit From NurOwn™ Treatment (NASDAQ:BCLI)
finance.yahoo.com - July 18 at 1:30 PM
insidermonkey.com logoA Look at Five Stocks Trending on Monday (NASDAQ:BCLI)
www.insidermonkey.com - July 18 at 12:57 PM
nasdaq.com logoWhat's In Store For BCLI: A Smooth Sailing Or Perfect Storm? (NASDAQ:BCLI)
www.nasdaq.com - July 18 at 8:45 AM
streetinsider.com logoBrainstorm Cell Therapeutics (BCLI) Announces NurOwn Phase 2 Met Primary Endpoint in ALS (NASDAQ:BCLI)
www.streetinsider.com - July 18 at 8:45 AM
marketwatch.com logoBrainstorm Cell Therapeutics' stock jumps after ALS drug trial results (NASDAQ:BCLI)
www.marketwatch.com - July 18 at 8:14 AM
biz.yahoo.com logoBRAINSTORM CELL THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements an (NASDAQ:BCLI)
biz.yahoo.com - July 18 at 8:13 AM
thestreet.com logoBrainstorm: New ALS Stem Cell Results Support Start of Pivotal Clinical Trial (NASDAQ:BCLI)
www.thestreet.com - July 18 at 8:01 AM
finance.yahoo.com logoBrainStorm Announces Positive Top Line Results from the U.S. Phase 2 Study of NurOwn® in Patients with Amyotrophic Lateral Sclerosis (ALS) (NASDAQ:BCLI)
finance.yahoo.com - July 18 at 8:00 AM
rttnews.com logoWatch Out For BCLI, RARE's Phase 3 Trial Hits Goal, JUNO Opens Wallet - RTT News (NASDAQ:BCLI)
www.rttnews.com - July 16 at 3:44 PM
News IconIncreased Volatility Noted on Shares of: Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - Engelwood Daily (NASDAQ:BCLI)
www.engelwooddaily.com - July 16 at 3:44 PM
thestreet.com logoBrainstorm Cell Therapeutics (BCLI) Stock Plummets Ahead of ALS Trial Results - TheStreet.com (NASDAQ:BCLI)
www.thestreet.com - July 16 at 3:44 PM
seekingalpha.com logoBrainstorm to unveil results from mid-stage NurOwn study in ALS on Monday; shares up big today (NASDAQ:BCLI)
seekingalpha.com - July 15 at 2:22 PM
rttnews.com logoWatch Out For BCLI, RARE's Phase 3 Trial Hits Goal, JUNO Opens Wallet (NASDAQ:BCLI)
www.rttnews.com - July 15 at 2:22 PM
streetinsider.com logoBrainstorm Cell Therapeutics (BCLI) Sets Date to Announce Top-Line NurOwn Phase 2 Data in ALS Patients - StreetInsider.com (NASDAQ:BCLI)
www.streetinsider.com - July 14 at 3:50 PM
finance.yahoo.com logoBrainStorm to Announce Top Line Results from the U.S. Phase 2 Study of NurOwn in Patients with Amyotrophic Lateral Sclerosis (ALS) on Monday, July 18 (NASDAQ:BCLI)
finance.yahoo.com - July 14 at 3:30 PM
News IconEye on Stock Volatility for: Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - Engelwood Daily (NASDAQ:BCLI)
www.engelwooddaily.com - July 14 at 12:41 PM
ftsenews.co.uk logoBrainstorm Cell Therapeutics (BCLI) Updated Price Targets - FTSE News (NASDAQ:BCLI)
www.ftsenews.co.uk - July 13 at 3:47 PM
News IconBrainstorm Cell Therapeutics Incorporated (NASDAQ:BCLI) Shorts Decreased by 9.6% After Short Covering - Consumer Eagle (NASDAQ:BCLI)
www.consumereagle.com - July 13 at 3:47 PM
News IconShares Dipping Lower in Session: Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - Telanagana Press (NASDAQ:BCLI)
telanaganapress.com - July 11 at 3:46 PM
News IconShares Dipping Lower in Session: Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - Telanagana Press (NASDAQ:BCLI)
telanaganapress.com - July 11 at 3:46 PM
fiscalstandard.com logoBroker Outlook For The Week Ahead Brainstorm Cell Therapeutics (BCLI) - Fiscal Standard (NASDAQ:BCLI)
www.fiscalstandard.com - July 5 at 3:45 PM
fiscalstandard.com logoRecently Issued Stock Ratings For Brainstorm Cell Therapeutics (BCLI) - Fiscal Standard (NASDAQ:BCLI)
www.fiscalstandard.com - June 30 at 3:57 PM
News IconBrainstorm Cell Therapeutics Inc Stock Is Crashing Now. What To Expect? - Press Telegraph (NASDAQ:BCLI)
presstelegraph.com - June 25 at 3:45 PM
biz.yahoo.com logoBRAINSTORM CELL THERAPEUTICS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statement (NASDAQ:BCLI)
biz.yahoo.com - June 24 at 4:11 PM

Social

BrainStorm Cell Therapeutics (NASDAQ:BCLI) Chart for Monday, September, 26, 2016


Last Updated on 9/26/2016 by MarketBeat.com Staff